Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 12/14/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.    Case No. 18-10518 (KG)
Debtor    Reporting Period: November 1, 2018 - November 30, 2018

MOR - 1

Consolidated Schedule of Cash Receipts and Disbursements (1)

For the Period: November 1, 2018 - November 30, 2018

(Unaudited)

 

           Cumulative  

$ USD ‘000s

   November 1, 2018 - November 30, 2018     Since Filing  

Beginning Cash Balance (Book)

   $ 29,014     $ 21,372  

Receipts

    

Operating Receipts

     —         64,084  

Miscellaneous Receipts

     72       71,226  
  

 

 

   

 

 

 

Total Receipts

     72       135,311  

Operating Disbursements

    

Payroll & Benefits / Contractors

     (31     (16,961

Inventory

     (572     (4,981

Manufacturing and Logistics

     —         (205

Gross to Net Disbursements

     —         (36,451

Marketing / Commercial Operations

     —         (16,236

Ordinary Course Professionals

     (9     (989

Rent / Facilities / Equipment

     —         (564

Insurance

     —         (364

IT / Utilities

     —         (376

Regulatory and Compliance

     —         (634

Other G&A

     (109     (1,309
  

 

 

   

 

 

 

Total Operating Disbursements

     (721     (79,070

Operating Cash Flow

     (649     56,241  

Reorganization Costs

    

DIP Loan Interest and Fees

     —         (44,480

US Trustee Fees

     —         (621

Restructuring Professional Fees

     (105     (10,001
  

 

 

   

 

 

 

Total Reorganization Costs

     (105     (55,102

Total Disbursements

   $ (826   $ (134,172
  

 

 

   

 

 

 

Lender Professional Fees

     (310     (2,160

Net Cash Flow

   $ (1,064   $ (1,022

DIP Draw - Cash

     —         7,600  
  

 

 

   

 

 

 

Ending Cash Balance (Book)

   $ 27,950     $ 27,950  

Notes:

 

(1)

The Schedule of Cash Receipts and Disbursements is presented on a book basis.